SecBot SecBot

GENB

Generate Biomedicines, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0002100782 Biotech & Drug Discovery
$12.07 −0.50 (−3.98%)
Nov 13 4:00 PM ET · prev $12.57
Market cap
$1.6B
Small cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
🔒 Subscribers only
Since first trade
−4.6%
from $12.65 · Feb 27
30 days
−3.9%
from $12.56
Range since listing
$11.21–20.38
−41% from high · low Mar 6
Avg volume 20D
924.7K
Oct 28 spike 3.94M
Short interest
9.08M
≈7.1% of shares · +1.7%
Days to cover
8.9
at average volume
Insider net
+$50.1M
5 buyers · 1 seller · since Feb 26
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 1 bearish · 2 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    5 insiders bought $50.3M at an average $15.97. 1 insider sold $200.7K. Price is 24% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 16 added (1 new), 3 trimmed or exited. Largest new: Banque Pictet & Cie Sa $26.6M.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +1.7% to 9.08M shares. 8.9 days to cover, ≈7.1% of shares.

  • TrendDOWNTREND

    16% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
$26.6M
in new stakes
FundMoveSharesValue
FMR LLCADD7,186,203$107.9M
JPMORGAN CHASE & COADD2,654,810$40.9M
VANGUARD CAPITAL MANAGEMENT LLCADD2,235,590$33.6M
ARK Investment Management LLCADD1,964,661$29.5M
BANQUE PICTET & CIE SANEW1,773,043$26.6M
MORGAN STANLEYADD522,410$7.8M
TD ASSET MANAGEMENT INCDOUBLED180,000$2.8M
ALPS ADVISORS INCADD170,042$2.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy3Buy8Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 5, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 8, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 28, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$50.3M
bought · 5 insiders
$200.7K
sold · 1 insider
−24.4%
vs their $15.97 cost
DateInsiderTypeValue
Oct 29, 2026
ARNOLD FRANCES
Director
Oct 29, 2026
SELL$184.7K
Sep 1, 2026
ARNOLD FRANCES
Director
Sep 1, 2026
SELL$16.0K
Mar 4, 2026
Nally Michael
Chief Executive Officer
Mar 4, 2026
BUY$240.0K
Mar 2, 2026
AFEYAN NOUBAR
Director
Mar 2, 2026
CONVERT18,483,785 sh
Mar 2, 2026
AFEYAN NOUBAR
Director
Mar 2, 2026
CONVERT2,109,704 sh
Mar 2, 2026
Grous Beth
Chief People Officer
Mar 2, 2026
BUY$4.8K
Mar 2, 2026
Nally Michael
Chief Executive Officer
Mar 2, 2026
CONVERT658,327 sh
Mar 2, 2026
AFEYAN NOUBAR
Director
Mar 2, 2026
CONVERT18,483,785 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
9,084,724
shares short
+1.7%
vs prior settlement
8.9
days to cover
≈7.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
3 drugs tracked · Drug pipeline →
Recent

SecBot reports

9 filings · 2 press releases · 1 bullish · 3 bearish · 5 neutral
All GENB filing & press-release reports (11)